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Abstract: Endometrial cancer arises from the uterine body and fundus in many cases, but can also originate from the 
lower region of the uterine body through the upper region of the cervix. Such tumors are referred to as carcinoma of the 
lower uterine segment (LUS) or isthmus, and account for 3-6.3% of all cases of endometrial cancer. This relatively low 
incidence has permitted performance of only small-scale studies, but the clinical and pathological characteristics of carci-
noma of the LUS in all these reports have differed from those of other endometrial cancers. Generally, endometrial cancer 
is classified into estrogen-dependent endometrioid adenocarcinoma (designated as type I), and non-endometrioid types 
that are less associated with estrogen and include poorly differentiated adenocarcinoma (type II). In some reports, carci-
noma of the LUS has been found to have type II characteristics. Carcinoma of the LUS has also been associated with 
Lynch syndrome, a hereditary disease with frequent development of colorectal, endometrial, and ovarian cancers. Lynch 
syndrome is thought to be induced by mismatch repair gene mutation. The frequency of Lynch syndrome in cases of gen-
eral endometrial cancer is 1-2%. In contrast, the frequency in patients with carcinoma of the LUS is much higher, with up 
to 29% of cases diagnosable with Lynch syndrome and a high frequency of hMSH2 mutation found in one study. This 
suggests that further investigation of the clinical and pathological characteristics of carcinoma of the LUS and the associa-
tion with Lynch syndrome is required through performance of a large-scale survey.  
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INTRODUCTION 
  The incidence of endometrial cancer is highest among 
malignant tumors arising in the female genital organs. In the 
US, 40,000 patients are diagnosed with endometrial cancer 
annually, and 7,500 patients die of this disease [1]. The en-
dometrium is pathologically divided into 2 regions: the uter-
ine corpus proper (UC) and lower uterine segment (LUS) 
[2]. Endometrial cancer generally arises from the UC endo-
metrium (the uterine body and fundus), but can originate 
from the LUS (the isthmus of the uterus) in rare cases. When 
a tumor localized in the LUS expands macroscopically from 
the lower uterine body through the upper cervix, it is re-
garded as carcinoma of the LUS. A tumor that is widely pre-
sent from the uterine body through the endocervix is ex-
cluded from the definition of carcinoma of the LUS because 
the primary site cannot be determined with certainty [3]. 
Since the LUS is located between the uterine body and cer-
vix, it shows histological characteristics of both the endo-
metrium and uterine cervix in the glandular epithelium and 
interstitium. In addition, the LUS tends to respond poorly to 
hormone stimulation because the mucosal layer of the endo-
metrium is thin compared to that of the uterine body [2]. 
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  Since endometrial cancer rarely develops from the LUS, 
only small-scale studies have been performed. However, the 
clinical and pathological characteristics of carcinoma of the 
LUS in these reports have differed from those of other en-
dometrial cancers. Endometrial cancer is generally classified 
into 2 groups [4]: type I cases of estrogen-dependent endo-
metrioid adenocarcinoma, which account for 70-80% of en-
dometrial cancer cases; and type II cases, including non-
endometrioid types and poorly differentiated adenocarci-
noma that are less associated with estrogen, which account 
for 10-20% of endometrial cancer cases. Continuous estro-
gen stimulation (unopposed estrogen) of the endometrium in 
the absence of progesterone is considered to be the cause of 
type I tumors, whereas type II cases arise from an atrophied 
endometrium and are often unrelated to estrogen. In some 
reports, carcinoma of the LUS lacks type I characteristics, 
but tends to show type II characteristics [5], which is as-
sumed to be due to the thin endometrial layer of the LUS and 
a weak endometrial response to estrogen. Clinically, type I 
cases are characterized by irregular menstruation inducing 
unopposed estrogen, nulliparity, infertility, and a high fre-
quency of PCOS (polycystic ovary syndrome). In contrast, 
type II cases show weak expression of estrogen and proges-
terone receptors, and p53 abnormality, and carcinoma of the 
LUS shows similar characteristics [3, 6-9]. 
  The association of carcinoma of the LUS with a heredi-
tary tumor, Lynch syndrome, has attracted recent attention. 
Lynch syndrome is a hereditary disease in which there is 
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cancers. The cause is thought to be a mismatch repair 
(MMR) gene mutation in germ cells and the frequency in 
cases of general endometrial cancer is 1-2% [10]. In contrast, 
Lynch syndrome has a high frequency in cases with carci-
noma of the LUS, with one report in the US suggesting that 
29% of cases could also be diagnosed with Lynch syndrome 
and that the hMSH2 mutation was present at a high fre-
quency [11]. Demonstration of an association between carci-
noma of the LUS and Lynch syndrome in a large-scale sur-
vey would allow patients with carcinoma of the LUS to be 
classified as a high-risk group for Lynch syndrome. 
PATHOLOGICAL DEFINITION AND CHARACTER-
ISTICS OF CARCINOMA OF THE LUS 
  A tumor localized in the LUS that expands macroscopi-
cally from the lower uterine body through the upper cervix is 
regarded as carcinoma of the LUS. A cancer that is widely 
present from the body through the endocervix is excluded 
from the definition of carcinoma of the LUS because the 
primary site cannot be identified [3]. The cavity of the uterus 
is histologically divided into 2 regions: the mucosa of the 
LUS, and that of the uterine body. The endometrium of the 
LUS is generally thinner than that of the fundus, and glands 
and interstitium in this region tend to respond slowly to hor-
mone stimulation, which is thought to delay endometrial 
development. There are 2 types of cells in the superficial and 
glandular epithelia in the isthmus of the uterus: columnar 
and ciliated cells. The endometrial layer of the LUS is simi-
lar to the endometrium with regard to cell distribution and 
histochemistry, but the volume of the endometrium tends to 
be smaller in the LUS [12]. Since the endocervical mucosa 
gradually transits to the endometrium of the LUS histologi-
cally, endocervical and endometrial features are mixed in the 
glandular epithelium and interstitium in the LUS [2]. 
  Pathologically, 80% of cases of endometrial cancer are 
classified as endometrioid adenocarcinoma. Histological 
grading for differentiation is applied only for endometrioid 
adenocarcinoma, and lesions are classified into G1 to G3 
based on the proportion of the solid region (FIGO staging). 
Squamous differentiation is a common finding. Such type I 
cases of endometrioid adenocarcinoma are moderately to 
well differentiated and often arise from background endo-
metrial hyperplasia due to long-term excess estrogen stimu-
lation. About 10% of cases of endometrial cancer are classi-
fied as type II and have a higher risk of recurrence and me-
tastasis compared to type I cases. Type II cases are not re-
lated to estrogen, but are caused by an atrophied endo-
metrium [4]. 
DISCRIMINATION BETWEEN CARCINOMA OF 
THE LUS AND CERVICAL ADENOCARCINOMA 
  It is often difficult to determine whether widely expanded 
adenocarcinoma centered in the uterine isthmus originated 
from the uterine body or cervix, even after pathological 
evaluation of a biopsied specimen. However, identification 
of the origin is important to establish an appropriate treat-
ment policy. After diagnosis of endometrial cancer, surgery 
is performed, the stage is identified, and adjuvant therapy is 
administered. In contrast, when cervical cancer is diagnosed, 
the clinical stage is identified before surgery, and chemora-
diotherapy without surgery is recommended for stages Ib, II 
or higher [13]. 
  There have been several reports on discrimination of en-
dometrial cancer from cervical cancer. Using MRI, Haider et 
al. found that endometrial hypertrophy, endometrial tumor, 
tumor advancement in the uterus, and muscular invasion via 
the endometrium occurred at a significantly higher frequency 
in endometrial cancer than in cervical adenocarcinoma, and 
that these characteristics were useful for discriminating be-
tween the two conditions [14]. In contrast, Westin et al. 
found that MRI was not necessarily useful for preoperative 
discrimination [11]. Immunohistologically, typical cases of 
endometrial cancer are positive for ER and vimentin and 
negative for CEA, whereas cervical cancer shows the oppo-
site pattern of negative for ER and vimentin and positive for 
CEA. Various small-scale studies have examined the opti-
mum combination of markers [15]. 
  Detection of HPV DNA and immunostaining for p16 
may also be useful for discriminating cervical adenocarci-
noma from endometrial cancer. HPV DNA is detected in 
cervical adenocarcinoma at a higher frequency than in en-
dometrial cancer. The p16 gene codes for a cyclin-dependent 
kinase inhibitor and there is a high risk of HPV infection 
with  p16 overexpression in cervical cancer. Expression of 
p16 protein also occurs in endometrial cancer based on im-
munostaining and may be associated with prognosis. Com-
parison of immunostaining results indicated diffuse p16 
overexpression in cervical cancer, but spotted and weak ex-
pression in endometrial cancer, and this may allow discrimi-
nation between the two diseases [16]. 
CLINICAL CHARACTERISTICS OF CARCINOMA 
OF THE LUS 
  The important prognostic factors in endometrial cancer 
are histologic type, grade of differentiation, and FIGO surgi-
cal stage [17]. Investigation of the pathological characteris-
tics of carcinoma of the LUS in comparison with non-LUS 
endometrial cancer is important to understand its characteris-
tics and prognosis. In 12 Japanese patients with carcinoma of 
the LUS, Hachisuga et al. [18] found a histologic type of 
adenosquamous carcinoma in 7 (58%) and differentiation to 
grade 3 in 7 (58%), both of which were higher than the re-
spective frequencies of 6% and 12% in non-LUS endo-
metrial cancer. Muscular invasion was found in all 12 pa-
tients [18]. In 5 patients with carcinoma of the LUS, Jacques 
et al. found that all were grade 3, with a histologic type of 
endometrioid adenocarcinoma accompanied by differentia-
tion to squamous epithelium in 3, a mixed tumor of serous 
and clear cell adenocarcinomas in 1, and MMMT in 1. All 5 
patients died within 23 months after diagnosis [3]. 
  In 13 patients with carcinoma of the LUS, Watanabe   
et al. found no significant differences in the frequencies of 
histologic types or differentiation grades, but higher rates of 
invasion of half or more of the muscular layer, lymph node 
metastasis, and positive ascites in cytology compared to non-
LUS cases [6]. Westin et al. also found no significant differ-
ences in the frequencies of concomitant endometrial hyper-
plasia, histologic types, or grades in 35 patients with carci-
noma of the LUS, but a higher frequency of stage II, deeper 
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space invasion, and a smaller tumor diameter compared to 
non-LUS cases [11]. In a study limited to patients with en-
dometrial cancer who were younger than 50 years old, the 
frequency of endometrioid adenocarcinoma differentiation to 
squamous epithelium was higher, muscular invasion was 
deeper, the grade was higher, and the frequency of concomi-
tant endometrial hyperplasia was lower in 16 patients with 
carcinoma of the LUS compared to cases of non-LUS endo-
metrial cancer, but there was no difference in the 10-year 
survival rate [5]. 
  The frequency of carcinoma of the LUS has been found 
to be 3-6.3% of all endometrial cancer cases [3, 11, 18]. In 
the largest comparison study (35 patients with carcinoma of 
the LUS vs. 974 patients with non-LUS endometrial cancer), 
the mean onset ages were 54.2 and 62.9 years old, respec-
tively, with a significantly younger age of onset for carci-
noma of the LUS [11]. The age of onset has varied in other 
studies [3, 5], but the proportion of cases of carcinoma of the 
LUS increased to 18% (16/88) in patients limited to those 
younger than 50 years old [5]. 
  Regarding risk factors, the cause of type I endometrial 
cancer is unopposed estrogen. Obesity increases insulin re-
sistance and an elevation of the blood estradiol level pro-
motes endometrial growth, leading to a risk of endometrial 
cancer that is 2 and 3 times greater with a BMI higher than 
25 and 30, respectively [19]. Nulliparity, amenorrhea, and 
infertility cause long-term estrogen stimulation and are risk 
factors for endometrial cancer. In a comparison of 16 pa-
tients with carcinoma of the LUS and 72 patients with non-
LUS endometrial cancer, Hachisuga et al. found that the 
frequencies of irregular menstruation, nulliparity, infertility, 
and PCOS were significantly lower in those with carcinoma 
of the LUS, showing that carcinoma of the LUS lacks the 
characteristics of typical type I endometrial cancer [5]. 
  The influence on prognosis of endometrial cancer dis-
semination to the LUS has also been investigated. Since 
stage II endometrial cancer is accompanied by cervical inva-
sion and expands to the LUS in most cases, most studies 
have been limited to patients with stage I endometrial cancer 
and have compared the prognosis between cases with (rates 
of 28-58%) and without LUS involvement [20-23]. Phelan et 
al. found that grade, lymphovascular space invasion, muscu-
lar invasion, and histologic type, but not LUS involvement, 
were related to the recurrence rate in stage I endometrial 
cancer [20]. Brown et al. also found that LUS involvement 
was not related to progression-free survival or recurrence 
rate [21], but that cases with LUS involvement had a high 
rate of lymph node metastasis [23]. 
CARCINOMA OF THE LUS AND HORMONE RE-
CEPTORS  
  Expression levels of estrogen (ER) and progesterone 
(PR) receptors change with the menstrual cycle in the normal 
endometrium, as shown by immunohistological staining. ER 
and PR are also expressed in type I endometrial cancer, 
which accounts for most cases of sporadic endometrioid 
adenocarcinoma and is associated with unopposed estrogen 
activity. In contrast, no or weak expression of ER and PR 
occurs in many cases of type II endometrial cancer [7]. Many 
studies have shown an association of ER and PR expression 
with the prognosis of endometrial cancer. However, some 
have shown that ER and PR levels are independent prognos-
tic factors, whereas others found a poor association with the 
prognosis; thus, the prognostic utility of ER and PR in en-
dometrial cancer is unclear [24]. In carcinoma of the LUS, 
Watanabe et al. found ER- and PR-positive rates of 23.1% 
(3/13) and 7.7% (1/13), respectively, compared to rates of 
54.5% (18/33) for both receptors in non-LUS endometrial 
cancer, showing a significant reduction of expression in car-
cinoma of the LUS [6]. Jacques et al. also found ER- and 
PR-positive rates of only 20% (1/5) in carcinoma of the LUS 
[3]. In contrast, Westin et al. reported an ER-positive rate of 
92% (24/26) in carcinoma of the LUS, with 73% (19/26) of 
the cases found to be ER-positive, vimentin-positive, and 
CEA-negative, similarly to the typical findings for endo-
metrioid adenocarcinoma of the uterine body [11]. These 
results indicate that a consistent conclusion has not been 
reached.  
CARCINOMA OF THE LUS AND p53 
 p53 is a tumor suppressor gene located on chromosome 
17. p53 protein inhibits proliferation and induces apoptosis 
of cells with DNA damage. Abnormal p53 is thought to be 
involved in carcinogenesis of endometrial cancer, and par-
ticularly in type II endometrial cancer including serous ade-
nocarcinoma. A p53 mutation has been observed in more 
than 60% of cases immunopositive for p53, and immunohis-
tochemical detection of p53 serves as a prognostic factor for 
endometrial cancer since it indicates a functional p53 ab-
normality [25]. Abnormal p53 expression was more fre-
quently observed in non-estrogen dependent type II endo-
metrial cancer and poorly differentiated (Grade 3) type I 
endometrial cancer [8]. In carcinoma of the LUS, Jacques  
et al. found that 60% (3/5) of cases had abnormal p53 pro-
tein [3]; Jiko et al. found a p53 mutation in 38% (3/8) of 
cases [9]; and Watanabe et al. found overexpression of p53 
in 61.5% (8/13) of cases, a frequency higher than that 
(18.2%, 6/33) in non-LUS endometrial cancer [6]. p53 muta-
tions also occur in cervical adenocarcinoma, but Jiko et al. 
stated that the p53 point mutation pattern in carcinoma of the 
LUS is more similar to that in endometrial cancer than in 
cervical adenocarcinoma [9]. 
CARCINOMA OF THE LUS AND LYNCH SYN-
DROME 
  Lynch syndrome or HNPCC is a hereditary disease that 
includes frequent development of colorectal, endometrial, 
and ovarian cancers. Lynch syndrome is caused by a heredi-
tary defect in the mismatch repair (MMR) gene and the inci-
dences in colorectal and endometrial cancers are 2-3% and 
1.8-2.1%, respectively [10]. In Lynch syndrome with a 
hMLH1 or hMSH2 mutation, the frequencies of colorectal 
and endometrial cancers are 68 and 62%, respectively, and 
the lifetime risk of developing endometrial cancer is higher 
than that for colorectal cancer in women [26]. In patients 
with Lynch syndrome, there have been fewer studies on en-
dometrial cancer compared to colorectal cancer due to prob-
lems with screening. The 1999 revised Amsterdam criteria II 
include endometrial cancer as a Lynch syndrome-related 
tumor, but women who develop endometrial cancer as the 
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detail are not included, and a high false negative rate has 
been reported based on these criteria [26]. For colorectal 
cancer, the Bethesda criteria require microsatellite instability 
(MSI) testing, but this is not applicable for patients who de-
velop endometrial cancer as the initial cancer. Thus, there is 
a need to establish criteria for selection of patients with en-
dometrial cancer who should undergo screening [27]. 
 Westin  et al. [11] diagnosed Lynch syndrome meeting 
the Amsterdam criteria II in 14.2% (5/35) of cases with car-
cinoma of the LUS. A hMSH2 gene mutation was present in 
all 5 cases, with MSI and a reduced hMSH2 protein level on 
immunostaining. Four further cases showed reduced hMSH2 
and hMSH6 levels on immunostaining and high MSI, 
strongly suggesting hMSH2 gene mutation, but did not meet 
the Amsterdam criteria II; and one case showed a reduced 
hMLH1 level despite the absence of aberrant DNA hyper-
methylation. All 10 patients (29%) were regarded to have 
Lynch syndrome [11]. The frequency of Lynch syndrome in 
carcinoma of the LUS was 14.2% even if limited to the 5 
cases with definite Lynch syndrome, which is very high 
compared to the frequency of 1-2% in general endometrial 
cancer. 
  In an immunohistological study of expression of mis-
match repair gene-encoded proteins (hMLH1, hMSH2, 
hMSH6, and PMS2), Garg et al. found carcinoma of the 
LUS in 5 of 32 patients with reduced protein expression, but 
only in 1 of 39 with normal protein expression, indicating an 
association between carcinoma of the LUS and Lynch syn-
drome [28]. On the other hand, Watanabe et al. found that 
24.2% (8/33) of non-LUS endometrial cancer cases were 
MSI-H compared to 0% (0/13) of carcinoma of the LUS 
cases in MSI analysis [6], suggesting a possible difference in 
genetic background between US and Japanese patients [11]. 
Only Westin et al. have previously proposed an association 
between carcinoma of the LUS and Lynch syndrome, and a 
further investigation of this association is required.  
CONCLUSION 
  Only small-scale studies on carcinoma of the LUS have 
been reported due to the rarity of this tumor among endo-
metrial cancers. Our review of these reports suggested that 
carcinoma of the LUS may show the clinicopathological 
characteristics of type II endometrial cancer and that the fre-
quency of associated Lynch syndrome may be high. Verifi-
cation of these findings is required through comparison of 
carcinoma of the LUS and general endometrial cancer in a 
large-scale study to investigate the dependence of the his-
tologic type and prognosis on the developmental site of en-
dometrial cancer, and to determine the frequency of Lynch 
syndrome in carcinoma of the LUS. A finding of a high fre-
quency will allow carcinoma of the LUS to be defined as a 
risk factor for Lynch syndrome, which may increase the 
screening sensitivity for Lynch syndrome. 
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